Targeting HLA class I expression to increase tumor immunogenicity.
about
The urgent need to recover MHC class I in cancers for effective immunotherapyPhenotypic T cell exhaustion in a murine model of bacterial infection in the setting of pre-existing malignancyInference of high resolution HLA types using genome-wide RNA or DNA sequencing readsImmune suppressive effect of cinnamaldehyde due to inhibition of proliferation and induction of apoptosis in immune cells: implications in cancerMurine lung cancer induces generalized T-cell exhaustion.CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancerImplication of the β2-microglobulin gene in the generation of tumor escape phenotypes.Adoptive T-cell transfer in melanoma.Advances in chimeric antigen receptor immunotherapy for neuroblastoma.Immune evasion in acute myeloid leukemia: current concepts and future directions.Immunology of hematopoietic stem cell transplant.Clinical and immunological significance of HLA-E in stem cell transplantation and cancer.Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies.Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma.HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance.Immunotherapy in renal cell cancer: the more the merrier?Personalized cancer vaccines: Targeting the cancer mutanome.Frequent HLA class I alterations in human prostate cancer: molecular mechanisms and clinical relevance.
P2860
Q26770165-AEEC9876-998D-43CA-8DDF-59273593C195Q27346770-84F52D6F-F6BB-464C-902C-DB0AB992FBE0Q33669140-928BE3EC-88B6-45A4-9E1E-DF3D587EE06BQ34278246-D064CC49-E772-467E-9A1D-706804003B4DQ35562860-CCC74C4E-755E-4C8F-9784-BA067FA50FEEQ36245546-DA004FBB-6038-4E32-BC90-252B1CE676C1Q38029543-62D86B7A-4FD8-4E8F-BEB4-B06563162080Q38068968-EC3B4D9C-046D-491B-9370-2305107EE0DEQ38170885-F1A03BF6-920F-4FD9-87EE-8B9C81A27F98Q38172521-1CD2B96B-5AAF-41F5-857C-172BEF136DF9Q38258161-D15C4D89-7B7F-4DE5-8684-4C1AE165FB5AQ38270003-8705E8AC-4F7C-47EB-9E12-8DCDCC57A4D7Q38962024-F22A5223-2A73-4E18-899E-311068659626Q39137410-46621374-93C9-40AE-9AE1-81F73C566494Q39201713-19894137-DC30-4720-B553-F07D2C86B88FQ40054303-BE27FA2E-CAB1-4236-9353-6BDC6284780BQ49956120-CA6E5261-B263-4DFC-A658-D1C77CE4AB72Q53807444-56C61C0F-F230-4D47-9B7C-DDA4A3A68EF8
P2860
Targeting HLA class I expression to increase tumor immunogenicity.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Targeting HLA class I expression to increase tumor immunogenicity.
@en
Targeting HLA class I expression to increase tumor immunogenicity.
@nl
type
label
Targeting HLA class I expression to increase tumor immunogenicity.
@en
Targeting HLA class I expression to increase tumor immunogenicity.
@nl
prefLabel
Targeting HLA class I expression to increase tumor immunogenicity.
@en
Targeting HLA class I expression to increase tumor immunogenicity.
@nl
P2093
P2860
P1433
P1476
Targeting HLA class I expression to increase tumor immunogenicity.
@en
P2093
A B del Campo
J Carretero
N Aptsiauri
P2860
P304
P356
10.1111/J.1399-0039.2011.01831.X
P577
2012-03-01T00:00:00Z